This study aimed to assess the performance of the GenoType MTBDRsl Line Probe Assay (LPA) for the detection of resistance to levofloxacin, amikacin, capreomycin and ethambutol on sputum specimens. Sputum samples from patients with smear positive multidrug-resistant tuberculosis, identified with GenoType MTBDRplus LPA, were further evaluated using the MTBDRsl LPA, while phenotypic drug susceptibility testing was used as control. Sputa with discordant outcomes were assessed by gene sequencing. 189 cases were included. The interpretability of the MTBDRsl LPA was 96.8%. The sensitivity and specificity of the MTBDRsl test were 82.5% and 91.5% for levofloxacin, 52.6% and 99.2% for amikacin, 58.1% and 97.7% for capreomycin, and 70.8% and 93.3% for ethambutol respectively. For the diagnosis of extensively drug-resistant tuberculosis, the sensitivity and specificity were 56.1% and 100%. The MTBDRsl LPA presents a specific screening tool to detect resistance to several key second-line anti-tuberculosis drugs and ethambutol in smear positive specimens.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diagmicrobio.2016.06.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Distribution of common and rare drug resistance patterns in clinical isolates revealed by GenoType MTBDR and MTBDR assay.
J Thorac Dis
October 2023
State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Background: Tuberculosis (TB) remains a significant global health emergency caused by (Mtb). The epidemiology, transmission, genotypes, mutational patterns, and clinical consequences of TB have been extensively studied worldwide, however, there is a lack of information regarding the epidemiology and mutational patterns of Mtb in Pakistan, specifically concerning the prevalence of multi-drug resistant TB (MDR-TB).
Methods: This study aimed to investigate the incidence of Mtb and associated mutational patterns using the line probe assay (LPA).
Genotype MTBDRsl version 2 and phenotypic drug resistance detection of for fluoroquinolones and aminoglycosides.
Int J Mycobacteriol
November 2023
ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India.
Background: Information on genotypic with comparison of phenotypic drug sensitivity test of anti-tuberculosis (TB) has been reported in several studies, which have variable results. The present study aimed to assess the Genotype MTBDRsl version 2.0/Line probe assay (LPA) for the detection of fluoroquinolones (FQ) and aminoglycosides (AMGs) resistance mutations among drug-resistant Mycobacterium TB (MTB) strains and also to compare the patterns of genotypic mutations of gyrA/B, rrs, and eis with mycobacteria growth indicator tube (MGIT 960).
View Article and Find Full Text PDFFluoroquinolone resistance mutations among and their interconnection with treatment outcome.
Int J Mycobacteriol
November 2023
Department of Respiratory Medicine, J. L. N. Medical College, Ajmer, Rajasthan, India.
Background: Fluoroquinolone (FQ) antibiotics are among the most potent second-line antitubercular drugs these days. The aim of the study was to analyze the frequency and pattern of genetic mutation in preextensive (pre-XDR) and extensively drug-resistant Mycobacterium tuberculosis using second-line line probe assay (LPA) and to compare drug-resistant mutations with different treatment outcomes.
Methods: Sputum, lymph node aspirate, and cold accesses from patients with rifampicin-resistant Tuberculosis (TB) were subjected to first-line and second-line LPA (Genotype MTBDRsl by Hain Life Science, Germany) to assess additional drug resistance to fluoroquinolones (levofloxacin and moxifloxacin).
Introduction: Multi-drug-resistant tuberculosis (MDR-TB) has become a major public health concern globally. Mutations in first- and second-line drug targets such as katG, inhA, rpoB, rrs, eis, gyrA, and gyrB have been associated with drug resistance. Monitoring predominant mutations in the MDR-TB patient population is essential to monitor and devise future therapeutic regimes.
View Article and Find Full Text PDFTo Test or Not? Xpert MTB/RIF as an Alternative to Smear Microscopy to Guide Line Probe Assay Testing for Drug-Resistant Tuberculosis.
J Clin Microbiol
July 2023
DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa.
Xpert MTB/RIF (Xpert) revolutionized tuberculosis (TB) diagnosis. Laboratory decision making on whether widely-used reflex drug susceptibility assays (MTBDR, first-line resistance; MTBDR, second-line) are conducted is based on smear status, with smear-negative specimens often excluded. We performed receiver operator characteristic (ROC) curve analyses using bacterial load information (smear microscopy grade, Xpert-generated semi-quantitation categories and minimum cycle threshold [C] values) from Xpert rifampicin-resistant sputum for the prediction of downstream line probe assay results as "likely non-actionable" (no resistance or susceptible results generated).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!